ESC Congress 2020

September 07, 2020

Dr. Gregory Weiss compiles thoughts and perspective on hot line trials presented at ESC Congress 2020.

September 06, 2020

Lead investigator of the PARALLAX trial discusses whether he feels clinical data related to sacubitril/valsartan is strong enough to warrant prescribing it for HFpEF patients.

September 04, 2020

Deepak Bhatt, MD, of Brigham and Women's Hospital, offers perspective on REDUCE-IT analyses and icosapent ethyl (Vascepa) data presented at ESC Congress 2020.

September 03, 2020

Milton Packer, MD, discusses how EMPEROR-Reduced data influences the way clinicians view the SGLT2 inhibitor class and its uses.

September 03, 2020

A podcast featuring an interview with Prof. Kausik Ray centered around the latest inclisiran data presented at ESC Congress 2020.

September 02, 2020

A study from ESC Congress 2020 details the effects of initiating rhythm control within the first year of an atrial fibrillation diagnosis.

September 02, 2020

Lead investigator of IMPACT-AFib discusses the results of the study and how they inform clinicians on strategies to improve oral anticoagulant use.

September 01, 2020

Investigators found no benefit from the discontinuation of ACE inhibitors/ARBs in patients hospitalized with COVID-19 in a prospective, randomized, phase 4 trial.

August 31, 2020

The largest and most comprehensive look at blood pressure therapies and cardiovascular disease risk to date is providing an overview of the effects of antihypertensive therapy at varying levels of baseline blood pressure.

August 31, 2020

Results of HOME-PE suggest an approach using HESTIA was noninferior to sPESI for patients with acute pulmonary embolism.